Can a two-glass urine test or leucocyte esterase test of first-void urine improve syndromic management of male urethritis in southern Thailand? NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Can a two-glass urine test or leucocyte esterase test of first-void urine improve syndromic management of male urethritis in southern Thailand?

Int J STD AIDS. 2000 Apr;11(4):235-40. Unique Identifier : AIDSLINE MED/20233040
Chandeying V; Skov S; Tabrizi SN; Kemapunmanus M; Garland S; Department of Obstetrics and Gynaecology, Faculty of Medicine,; Prince of Songkla University, Hat Yai, Thailand.


Abstract: The goal of this study was to determine whether a urine two-glass test or a leucocyte esterase (LE) test of first-void urine (FVU) improve the sensitivity or specificity of the World Health Organization (WHO) algorithm for the syndromic management of men with urethritis in southern Thailand. A secondary aim was to determine whether infection with Trichomonas vaginalis was sufficiently common to include treatment for it in a syndromic management protocol. One hundred and twenty-nine men with symptoms of urethritis seen at 2 STD clinics in Songkla Province, Thailand were enrolled. Symptoms and signs of each man were recorded and a urethral swab collected for microscopy and culture for Neisseria gonorrhoeae. A two-glass urine test and an LE test of an FVU specimen were performed. The FVU was tested by polymerase chain reaction (PCR) for N. gonorrhoeae, Chlamydia trachomatis and T. vaginalis. Dysuria was a symptom in 78% of men. A urethral discharge was a symptom in 68% but was evident on examination in 95% of the men. The prevalences of infection were 32.6% for N. gonorrhoeae, 23.3% for C. trachomatis, 1.6% for T. vaginalis and 51.9% for any infection. The sensitivities and specificities of urethral discharge on examination, two-glass test and LE test of FVU as indicators of infection with either or both of N. gonorrhoeae or C. trachomatis were 97% and 8%; 57% and 83%; and 59% and 78% respectively. Combinations of urethral discharge on examination and one of the other indicators were more specific but much less sensitive than the presence of discharge alone. Culture for N. gonorrhoeae was found to be only 43% sensitive compared with an expanded gold standard involving a PCR test. Our analysis demonstrates that neither the two-glass test nor the LE test of FVU were useful in improving on the WHO algorithm for management of men with urethritis. T. vaginalis was not common enough to include in a first-line syndromic management protocol for male urethritis. We recommend that, in southern Thailand, men with symptoms of urethritis in whom a urethral discharge is present on examination be offered immediate treatment for both N. gonorrhoeae and C. trachomatis as per the WHO algorithm.
Keywords: JOURNAL ARTICLE Animal Carboxylic Ester Hydrolases/*URINE Chlamydia trachomatis/GENETICS Chlamydia Infections/MICROBIOLOGY/PHYSIOPATHOLOGY/THERAPY/*URINE Disease Management Gonorrhea/MICROBIOLOGY/PHYSIOPATHOLOGY/THERAPY/*URINE Human Male Neisseria gonorrhoeae/GENETICS Support, Non-U.S. Gov't Thailand Trichomonas vaginalis/GENETICS Trichomonas Infections/PHYSIOPATHOLOGY/PARASITOLOGY/THERAPY/ *URINE Urethritis/ETIOLOGY/PHYSIOPATHOLOGY/THERAPY/*URINE

KWDjournalarticleanimalcarboxylicesterhydrolases/KWDurinechlamydiatrachomatis/geneticschlamydiainfections/microbiology/physiopathology/therapy/KWDurinediseasemanagementgonorrhea/microbiology/physiopathology/therapy/KWDurinehumanmaleneisseriagonorrhoeae/geneticssupport,non-uKWDsKWDgov'tthailandtrichomonasvaginalis/geneticstrichomonasinfections/physiopathology/parasitology/therapy/KWDurineurethritis/etiology/physiopathology/therapy/KWDurine
000930
A0091508


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .